Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Carfilzomib and a PI3Kdelta Inhibitor TGR-1202 in the Treatment of Patients With Relapsed or Refractory Lymphoma

NCT02867618 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT02867618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02867618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Carfilzomib and a PI3Kdelta Inhibitor TGR-1202 in the Treatment of Patients With Relapsed or Refractory Lymphoma
Lead sponsor
Columbia University
Phase
Phase 1/2
Overall status
Terminated
Start date
October 16, 2016
Completion date
June 30, 2020
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin disease, lymphoma, non-hodgkin